NPPB and carcinoid syndrome: Though not a NET biomarker sensu stricto, the N-terminal prohormone of brain natriuretic peptide (NT-proBNP) should be measured for the diagnosis and monitoring of carcinoid heart disease in carcinoid syndrome patients [163].